Featured Trial:
Melanoma Treatment

Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Sarcoma Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

NAME

-->

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

October 15, 2024

Categories

News Stories

Cooperative Groups develop consensus nomenclature for radiation targets on future lymphoma clinical trials

October 11, 2024

Categories

News Stories

Journal of Clinical Oncology publishes RTOG 1106/ACRIN 6697 results: Midtreatment PET-adapted radiotherapy dose escalation fails to improve outcomes for lung cancer patients

October 11, 2024

Categories

News Stories

Mid-treatment PET-adapted radiotherapy dose escalation fails to improve outcomes for lung cancer patients: Results of NRG-RTOG1106/ECOG-ACRIN 6697

October 10, 2024

Categories

News Stories

Women in Medicine Month: Celebrating Women Advancing Radiology

September 26, 2024

Categories

The Fall 2024 advocacy blog Considering Clinical Trials is now available

September 20, 2024

Categories

Announcements

The September 2024 News from ECOG-ACRIN blog is now available

September 18, 2024

Categories

Press Releases

Press Release: Cancer Cooperative Group leaders propose a re-engineering of the nation’s correlative science program for cancer

September 10, 2024

Categories

Press Releases

Press Release: Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Tweets

ECOG-ACRIN Cancer Research Group Follow 7,343 6,231

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

4h 1846249935622049898

.@skmaithel of @WinshipAtEmory is leading EA2197/OPT-IN, a #ClinicalTrial for patients with incidentally discovered stage 2-3 #GallbladderCancer. Find more information here: https://bit.ly/EA2197 #gicsm

Reply on Twitter 1846249935622049898 Retweet on Twitter 1846249935622049898 0 Like on Twitter 1846249935622049898 0 Twitter 1846249935622049898

; ECOG-ACRIN Cancer Research Group @eaonc ·

6h 1846219821047828812

Have you had surgery for squamous cell carcinoma of the head and neck (#HNSCC) that has come back? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://bit.ly/ea3191-study #HeadAndNeckCancer #HNCA

Reply on Twitter 1846219821047828812 Retweet on Twitter 1846219821047828812 0 Like on Twitter 1846219821047828812 0 Twitter 1846219821047828812

; ECOG-ACRIN Cancer Research Group @eaonc ·

7h 1846204591429296303

The #ComboMATCH Study, led by researchers from @StanfordCancer, @MDAndersonNews, @PennCancer, & @NCItreatment, is testing new combinations of anti-#cancer drugs, based on the characteristics of patients’ tumors. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine

Reply on Twitter 1846204591429296303 Retweet on Twitter 1846204591429296303 0 Like on Twitter 1846204591429296303 1 Twitter 1846204591429296303

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).